• US filing for ViiV’s two-drug, single pill HIV treatment pharmatimes
    November 01, 2018
    ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV...
PharmaSources Customer Service